TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25227627

Group type: EXPERIMENTAL
Intervention: Nalmefene plus psychosocial support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychosocial support alone
Number of subjects: 0
Study: 23190528

Group type: EXPERIMENTAL
Intervention: Virtual reality models for planning tumor resection
Number of subjects: 60
Study: 19907167

Group type: EXPERIMENTAL
Intervention: Aspirin in combination with rt-PA thrombolysis
Number of subjects: 800

Group type: COMPARATOR
Intervention: rt-PA thrombolysis alone
Number of subjects: 800
Study: 17691590

Group type: EXPERIMENTAL
Intervention: Iron(III)‐hydroxide polymaltose complex (IPC) administered with orange juice (enhancer)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Iron(III)‐hydroxide polymaltose complex (IPC) administered with food
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Iron(III)‐hydroxide polymaltose complex (IPC) administered during fasting
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Iron(III)‐hydroxide polymaltose complex (IPC) administered with black tea (inhibitor)
Number of subjects: 32
Study: 16254756

Group type: EXPERIMENTAL
Intervention: Graded activity intervention
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study: 11908739

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) as a single agent for three months
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Vindesine during induction
Number of subjects: 58
Study: 10440409

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional dual or triple cyclosporine A immunosuppressive therapy
Number of subjects: 0
Study: 7540478

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (2 IU/M2) continued until variant GH production from the placenta was evident.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (2 IU/M2) during pregnancy.
Number of subjects: 1
Study: 2129647

Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms b.d.
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms b.d.
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 31425040

Group type: EXPERIMENTAL
Intervention: Motorized Ankle Stretcher (MAS) technology
Number of subjects: 16

Group type: COMPARATOR
Intervention: Stretching board (Control)
Number of subjects: 16
Study: 29261736

Group type: COMPARATOR
Intervention: Oral vancomycin (250mg every 6 h for 10-14 days)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: FMT‐FURM (Fecal microbiota transplant)
Number of subjects: 19
Study: 25223524

Group type: EXPERIMENTAL
Intervention: Dotarem(®)
Number of subjects: 41

Group type: COMPARATOR
Intervention: MultiHance(®)
Number of subjects: 41
Study: 24028842

Group type: EXPERIMENTAL
Intervention: Presence of a medical clown during intravenous catheter insertion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Absence of a medical clown during intravenous catheter insertion
Number of subjects: 0
Study: 21753188

Group type: EXPERIMENTAL
Intervention: lenalidomide 10 mg/day
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: lenalidomide 5 mg/day
Number of subjects: 205

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: lenalidomide (combined groups)
Number of subjects: 205
Study: 19013718

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tramadol 50mg QID
Number of subjects: 18

Group type: COMPARATOR
Intervention: Diphenhydramine (active placebo)
Number of subjects: 18
Study: 16256435

Group type: EXPERIMENTAL
Intervention: PPD-S and PPD-B dual testing
Number of subjects: 17530

Group type: EXPERIMENTAL
Intervention: PPD-B with induration <10mm
Number of subjects: 17530

Group type: EXPERIMENTAL
Intervention: Non-tuberculous mycobacteria infection
Number of subjects: 17530
Study: 15290114

Group type: EXPERIMENTAL
Intervention: Quantitative Gated SPECT (QGS), Emory Cardiac Toolbox (ECT), Stanford University (SU-Segami) Medical School algorithm
Number of subjects: 31
Study: 11726828

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 5599

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 5599
Study: 9143888

Group type: EXPERIMENTAL
Intervention: Indirect laser treatment (scatter photocoagulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 0
Study: 8191269

Group type: EXPERIMENTAL
Intervention: Propofol (15 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intralipid (1.5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study: 3075406

Group type: EXPERIMENTAL
Intervention: Dihydralazine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lopirin (SQUIBB)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tensiomin (EGIS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dihydralazine + Lopirin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dihydralazine + Tensiomin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dihydralazine + Placebo
Number of subjects: 15
Study: 31776882

Group type: EXPERIMENTAL
Intervention: Preschool Peer Social Intervention (PPSI) for play, interaction, or conversation over 6 months
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Preschool Peer Social Intervention (PPSI)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Waitlisted-treatment-as-usual control group
Number of subjects: 65
Study: 30112398

Group type: EXPERIMENTAL
Intervention: Digital workflow (monolithic zirconia crown)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Analog workflow (metal-ceramic crown)
Number of subjects: 50
Study: 27405049

Group type: EXPERIMENTAL
Intervention: Self-care skills training with solution-focused counselling
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 25572415

Group type: EXPERIMENTAL
Intervention: 20 CPD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 CPD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 CPD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0 CPD
Number of subjects: 0

Group type: COMPARATOR
Intervention: 19-25 CPD
Number of subjects: 0
Study: 22963932

Group type: EXPERIMENTAL
Intervention: 5 mg vortioxetine
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 20689757

Group type: EXPERIMENTAL
Intervention: Cisplatin and methotrexate (CM)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Methotrexate, vinblastine, epirubicin, and cisplatin (M-VEC)
Number of subjects: 108
Study: 18464745

Group type: EXPERIMENTAL
Intervention: Irbesartan monotherapy for 12 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Irbesartan in homozygous AT1R 5245 T allele patients
Number of subjects: 42
Study: 16848888

Group type: EXPERIMENTAL
Intervention: Stepped care programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (GP care)
Number of subjects: 0
Study: 12946228

Group type: EXPERIMENTAL
Intervention: Combined Pap test and HPV testing
Number of subjects: 257

Group type: COMPARATOR
Intervention: Pap test alone
Number of subjects: 257
Study: 10459028

Group type: EXPERIMENTAL
Intervention: Hysteroscopic removal of tamoxifen‐associated endometrial polyps with concomitant endometrial resection (10 women)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No concomitant endometrial resection (Control group, 10 women)
Number of subjects: 20
Study: 8666137

Group type: EXPERIMENTAL
Intervention: CDP571 (5 mg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 21
Study: 2052335

Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 105
Study: 6190466

Group type: EXPERIMENTAL
Intervention: 6% hetastarch (HES)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 5% plasma protein fraction (PPF)
Number of subjects: 32
Study: 31521683

Group type: EXPERIMENTAL
Intervention: Carillon device
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 120
Study: 29360778

Group type: EXPERIMENTAL
Intervention: P280 (70 g whey protein, 280 kcal)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: M280 (14 g protein, 28 g carbohydrate, 12.4 g fat, 280 kcal)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: M504 (70 g protein, 28 g carbohydrate, 12.4 g fat, 504 kcal)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (2 kcal)
Number of subjects: 13
Study: 26796870

Group type: EXPERIMENTAL
Intervention: Hydrogel spacer (HS)
Number of subjects: 20
Study: 24158782

Group type: EXPERIMENTAL
Intervention: Dynamic orthosis (group A "Innovator X")
Number of subjects: 26

Group type: COMPARATOR
Intervention: Plaster splint (group B)
Number of subjects: 26
Study: 23095791

Group type: EXPERIMENTAL
Intervention: A‐CHOP (CHOP plus amifostine)
Number of subjects: 34

Group type: COMPARATOR
Intervention: CHOP (classical CHOP)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: A‐CHOP
Number of subjects: 34

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 34
Study: 20128031

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17344251

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 31

Group type: COMPARATOR
Intervention: ST
Number of subjects: 31
Study: 16632108

Group type: EXPERIMENTAL
Intervention: VDV3 vaccine
Number of subjects: 0
Study: 12791632

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg Zn daily during the second half of pregnancy)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 355
Study: 10561270

Group type: EXPERIMENTAL
Intervention: Intensive consolidation chemotherapy (CC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (allo BMT)
Number of subjects: 25
Study: 8565760

Group type: EXPERIMENTAL
Intervention: Sulglycotide 400 mg three times a day for one year
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sulglycotide
Number of subjects: 10
Study: 2007672

Group type: EXPERIMENTAL
Intervention: Topical metronidazole (1% cream), applied twice daily
Number of subjects: 108

Group type: COMPARATOR
Intervention: Oral tetracycline (250 mg, taken twice daily)
Number of subjects: 108
Study: 6350473

Group type: EXPERIMENTAL
Intervention: 10 mg/kg acyclovir intravenously three times daily for five days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29105802

Group type: EXPERIMENTAL
Intervention: Androgen deprivation combined with cixutumumab
Number of subjects: 50

Group type: COMPARATOR
Intervention: Androgen deprivation alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Analysis of 365 miRNAs
Number of subjects: 50
Study: 28870163

Group type: EXPERIMENTAL
Intervention: ProSeal LMA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supreme LMA
Number of subjects: 0
Study: 26595206

Group type: EXPERIMENTAL
Intervention: Continuous resistance training for 10 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Retraining resistance training (5 weeks training, 2 weeks detraining, 5 weeks training)
Number of subjects: 60
Study: 24277404

Group type: EXPERIMENTAL
Intervention: Jejunal interposition
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Esophageal with the posterior of residual-stomach
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Roux-en-Y esophagojejunostomy
Number of subjects: 123

Group type: COMPARATOR
Intervention: All methods
Number of subjects: 123
Study: 20622200

Group type: EXPERIMENTAL
Intervention: Tecarfarin (50 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Warfarin (17.5 mg)
Number of subjects: 20
Study: 19106861

Group type: EXPERIMENTAL
Intervention: Bowel preparation
Number of subjects: 5000

Group type: COMPARATOR
Intervention: No bowel preparation
Number of subjects: 5000
Study: 16595163

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects (age- and sex-matched)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Genotyping of three SNP markers
Number of subjects: 20
Study: 12928713

Group type: EXPERIMENTAL
Intervention: morphine 0.2 mg IT in addition to hyperbaric bupivacaine 10 mg IT
Number of subjects: 45

Group type: COMPARATOR
Intervention: hyperbaric bupivacaine 10 mg IT
Number of subjects: 45
Study: 11754675

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 microgram total dose, 2 puffs in each nostril once daily for 21 days)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo nasal spray (2 puffs in each nostril once daily for 21 days)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 95
Study: 9481097

Group type: EXPERIMENTAL
Intervention: Azathioprine (1.5 mg/kg/day) with prednisolone (2 mg/kg on alternate days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Pulse intravenous cyclophosphamide (500 mg/m2 body surface area monthly) with prednisolone (2 mg/kg on alternate days)
Number of subjects: 29
Study: 8320445

Group type: EXPERIMENTAL
Intervention: Radical neck dissection
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conservative neck dissection
Number of subjects: 104
Study: 3743615

Group type: EXPERIMENTAL
Intervention: oxprenolol Oros, 16/260 mg/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: atenolol, 100 mg/day
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 28651844

Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 26709241

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (21 g/day for 8 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (iso-nitrogenous)
Number of subjects: 39
Study: 24709430

Group type: EXPERIMENTAL
Intervention: Supervised toothbrushing with 1,400 ppm/31 percent fluoride xylitol toothpaste
Number of subjects: 196

Group type: COMPARATOR
Intervention: Supervised toothbrushing with 1,450 ppm fluoride sorbitol toothpaste
Number of subjects: 196
Study: 24169071

Group type: EXPERIMENTAL
Intervention: Proprioceptive exercises rehabilitation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (non-injured subjects)
Number of subjects: 16
Study: 21145054

Group type: EXPERIMENTAL
Intervention: Single-balloon colonoscopy (SBC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Crossover to SBC after SC failure
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 19052124

Group type: EXPERIMENTAL
Intervention: Benazepril plus amlodipine
Number of subjects: 11506

Group type: COMPARATOR
Intervention: Benazepril plus hydrochlorothiazide
Number of subjects: 11506
Study: 16365068

Group type: EXPERIMENTAL
Intervention: Lignan complex (500 mg/d of SDG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (low-fat muffin without lignan complex)
Number of subjects: 22
Study: 14682107

Group type: EXPERIMENTAL
Intervention: Postexcisional radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No radiation therapy (excision alone)
Number of subjects: 0
Study: 10827148

Group type: EXPERIMENTAL
Intervention: PR + IM
Number of subjects: 95

Group type: COMPARATOR
Intervention: PR
Number of subjects: 95
Study: 8981490

Group type: EXPERIMENTAL
Intervention: Vitamin B12 (methylcobalamin; 0.5 mg/day intravenously for 11 days, followed by 2 mg x 3/day orally for 7 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 8
Study: 1294918

Group type: EXPERIMENTAL
Intervention: Fentanyl (2 micrograms/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 28
Study: 3921146

Group type: EXPERIMENTAL
Intervention: Behavioural psychotherapy from a nurse therapist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine treatment from a general practitioner
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crossover behavioural treatment from the nurse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dropped out or refused therapy
Number of subjects: 0
Study: 31672711

Group type: EXPERIMENTAL
Intervention: Provision of a progestogen-only pill (POP, desogestrel) plus rapid access to a local sexual and reproductive health (SRH) clinic.
Number of subjects: 626

Group type: COMPARATOR
Intervention: Provision of emergency contraception (levonorgestrel) alone (standard care).
Number of subjects: 626
Study: 30424728

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Bifidobacterium longum subsp. infantis BB‐02, Streptococcus thermophilus TH‐4, Bifidobacterium animalis subsp. lactis BB‐12)
Number of subjects: 1099

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1099
Study: 27568318

Group type: EXPERIMENTAL
Intervention: Position change after angiography
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supine position with complete bed rest (Control)
Number of subjects: 60
Study: 25462029

Group type: EXPERIMENTAL
Intervention: Modified mindfulness-based stress reduction (MBSR) intervention
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral stress-eating intervention (SEI)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Combined intervention (MBSR + SEI)
Number of subjects: 53
Study: 22531334

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing
Number of subjects: 30

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study: 20519067

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 28
Study: 18598851

Group type: EXPERIMENTAL
Intervention: Single training session followed by sleep
Number of subjects: 2

Group type: COMPARATOR
Intervention: Two rotation adaptation training sessions
Number of subjects: 2
Study: 16442958

Group type: EXPERIMENTAL
Intervention: Self-report group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Shadow group
Number of subjects: 34
Study: 14647028

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11146310

Group type: EXPERIMENTAL
Intervention: Calcitriol therapy as a single weekly dose of 0.08 microg/kg b.w. (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Calcitriol therapy divided into two equal doses (Group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Calcitriol therapy divided into three doses (Group C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of PTH % variation among the three groups
Number of subjects: 30
Study: 8772602

Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 5 alpha-dihydrotestosterone
Number of subjects: 12
Study: 1531069

Group type: EXPERIMENTAL
Intervention: Protocol 1 (rest/exercise)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Protocol 2 (exercise/rest)
Number of subjects: 11
Study: 6382197

Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (V.I.P.) intravenously at 6 pmol kg‐1 min‐1 for 15 minutes
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (V.I.P.)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31684932

Group type: EXPERIMENTAL
Intervention: Participatory learning and action (PLA) intervention
Number of subjects: 0
Study: 28043751

Group type: EXPERIMENTAL
Intervention: Silicate‐substituted calcium phosphate (Si‐CaP) as a bone graft substitute
Number of subjects: 40

Group type: COMPARATOR
Intervention: Autologous bone from the iliac crest
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Silicate‐substituted calcium phosphate (Si‐CaP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Autologous bone
Number of subjects: 40
Study: 26691646

Group type: EXPERIMENTAL
Intervention: Kiosk-based interactive patient education intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Attention-control
Number of subjects: 200
Study: 24251428

Group type: EXPERIMENTAL
Intervention: Laser lithotripsy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pneumatic lithotripsy
Number of subjects: 60
Study: 21531124

Group type: EXPERIMENTAL
Intervention: budesonide/formoterol pMDI 320/9μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: budesonide/formoterol pMDI 160/9μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: formoterol dry powder inhaler (DPI) 9μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: budesonide/formoterol pMDI
Number of subjects: 0

Group type: COMPARATOR
Intervention: formoterol
Number of subjects: 0
Study: 18623907

Group type: EXPERIMENTAL
Intervention: Meningitis B vaccine (two doses)
Number of subjects: 171800

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 171800
Study: 17031257

Group type: EXPERIMENTAL
Intervention: Exercise intervention, details not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 0
Study: 14572890

Group type: EXPERIMENTAL
Intervention: 40 mg isosorbide mononitrate, given intravaginally 12 h before induction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo, given intravaginally 12 h before induction
Number of subjects: 100
Study: 10639021

Group type: EXPERIMENTAL
Intervention: 50 mg DHEA
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 100 mg DHEA
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 8606314

Group type: EXPERIMENTAL
Intervention: Telephone administration of SF-36
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Face-to-face administration of SF-36
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Self-administration of SF-36
Number of subjects: 172
Study: 1417339

Group type: EXPERIMENTAL
Intervention: Indirect endolymphatic therapy with bicillin‐3
Number of subjects: 137

Group type: COMPARATOR
Intervention: Routine penicillin therapy
Number of subjects: 137
Study: 6198058

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Quadruple chemotherapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Serum alpha-fetoprotein levels
Number of subjects: 39